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The prognosis in cancer depends on so many factors, some still unknown,
that it is seldom possible to express an authoritative opinion on the outcome in
any individual case. To define and to assess the importance of different factors
requires the collection of large masses of data so that subsequent tabulation and
analysis may be independent of variations due to chanoe or individual selection,
as far as possible.
Since 1945 the National Cancer Registration Scheme has been collecting
records of the clinical conditions of patients when they are first seen at a hospital
or clinic, their treatment and their subsequent progress. In the first year of the
scheme some 23,000 records were received but by the end of I953 the annual
number ofrecorded cancer cases had risen to more than 60,000.
This note is concerned with cases recorded between 1945 and 1949, the clinical
stage of the disease at registration and the patient's statement of the duration of
symptoms prior to registration. Five year survival rates are given only for those
patientsregistered prior to 1948. Seven sites have been selected for examination,
stomach, largeintestine, rectum, lungandbronchus, skin, cervix uteriandprostate.
These sites in men account for more than 70 per cent and in women more than
50 per cent of all deaths ascribed to cancer.
Three clinical stages are distinguished in the following tables (a) early, where
the growth is still confined to the organ of origin; (b) late, where local extension
has extended beyond the organ of origin; (c) metastatic, where metastases in
distant organs are recorded at the time of registration. In this grouping no
account has been taken of the presence or absence of affected regional lymph
nodeswhichwere rarelydiagnosedin early cases andformedbut a small proportion
oflate cases.
Very few cases ofepithelioma ofthe skin (only 68) with evidence of metastatic
spread were recorded and analysis ofthis group has been omitted from the tables.
The average duration of symptoms has been expressed in months, by the
median interval. The median is that period which is exceeded by exactly one
half the observations and, where the distribution of a measurement is markedly
asymmetrical, as is the case here, is a more reliable estimate of the average than
the arithmetic mean. This is shown in Table I together with the percentage of
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casesineachstage withadeclared historyof(a)less thantwo months, (b) more than
12 months and (c) more than two years.
The crude survival rates in Table II are given for both sexes together and are
shown (a) for those with a symptomatic history of less than two months, (b)
with histories between 2 and 6 months, (c) between 6 and 12 months and (d) those
with symptoms lasting one year or more.
Duration of Symptoms
In Table I, which shows separately for each sex the median duration of the
three stages ofeach site group, it is noticeable that women tend to report a longer
duration ofsymptoms than men. Except in the case of the early stages of cancer
ofskin and rectum the difference between the median values is small, considerably
less than one month, but it is almost invariably present. It is also noteworthy
TABLE I.-Average Duration of Symptoms (Median) and Percentage of Patients
with Very Long and Very Short Histories (i.e.) of; (a) less than Two Months,
(b) more than Twelve Months, (c) more than Two Years.
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that with the exception of cancer of the large intestine and the late cases of
epithelioma ofthe skin, the median varies little from site to site but is commonly
of about six months' duration.
Using the median interval as the criterion, these seven sites fall into three
broad groups.
I. Where the median duration of symptoms among those with meta-
static spread is at least a month shorter than among those whose
growthis stillinthe early stage, thelate stages having anintermediate
duration.
II. Where the median durations for the three stages differ by less than
a month.
III. Where the median duration is shortest in the early stage and longer
in the late or metastatic stage.
I.-In cancer of the stomach and cancer of the lung and bronchus in both
sexes, the median duration of symptoms decreases with the increasing extent of
the lesion. In cancer of the stomach the average duration among early cases is
1.7 months (males) and 1.9 months (females) longer than among those with overt
metastases, the average duration of the late cases without metastases being
intermediate. In cancer of the lung and bronchus the differences are 1.4 months
in both cases. Also there is in the metastatic group, at both sites, a larger propor-
tionof cases with a very short history and a smaller proportion with a longhistory
than in either of the two other groups.
For cancer at each of these sites the proportion of cases seen in the early
stage is small (stomach 14 per cent and lung 12 per cent) while the 5 year survival
rates are very low.
II.-Among persons of both sexes with cancer ofthe intestine and among men
with rectal and prostatic cancer the median durations for the different stages
differ by considerably less than a month. In intestinal cancer the proportion
of cases with a history of under two months is less among those with metastases
than among those in the other stages but the proportions of cases with a very
long history differ very little.
The median duration of cancer ofthe male rectum and the proportion of cases
with short or long histories vary little from stage to stage, while in prostatic
cancer both the proportions of cases with very long or very short histories are
smaller in the metastatic group than among those with early or late growths.
In cancer of the female rectum the median duration amongst those with
metastases is nearly a month less than amongst those in the early and late stage
but the proportion ofcases with very long and very short histories is not markedly
different among those in the early and metastatic stages.
At all these sites, more cases are seen in the early stage than with metastases.
Moreover the 5 year survival rates are very much higher than among the lung
and stomach cases.
III.-In cancer of the cervix uteri and cancer ofthe skin the median duration
is considerably less among early than among late or metastatic cases and the
proportion of metastatic cases seen at either site is very small. In cancer of the
cervix there is little difference between the proportions of those with a very short
history whether seen in the early or metastatic stage though the metastatic
group contains a greater proportion of cases with long histories. The 5 year
403404 A. McKENZIE
survival rate for cancer ofthe cervix is higher than for any ofthe five sites already
considered.
Survival Rates
In Table II the 5 year crude survival rates of early cases receiving radical
treatment are given in the first line of each section. They consist of cases where
the extent of the growth was limited and where it was hoped that treatment
might completely cure the condition. The survival rates vary according to the
length of symptomatic history but in a different manner at different sites. In
cancer of the stomach, intestine and rectum survival rates are better the longer
the symptomatic history, it is only among the early epithelioma of the skin that
the survival rate is higher when the history is short. In prostatic cancer those
cases with a short or long history (less than two months or more than one year)
have higher survival rates than those of intermediate duration. In cervical
cancer the survival rate appears to be almost independent of the lengthof history
and in cancer of the lung and bronchus though no distinct pattern is seen the
survival rate of cancer treated within six months of the onset of symptoms is
higher than those treated later.
TABLE II.-Crude (5 year) Survival RatesofEarly and Late Cases receiving Radicat
Treatment and of All Cases whether Treated or not, according to the Duratiom
ofSymptoms, expressed aspercentages of Cases Registered.
Duration of symptoms in months.
Stage. 0. 2. 6. 12+. No. of cases.
Stomach
Early . . 14*3 24- 0 23-1 32-1 485
Late . . 8.3 6 7 8-2 17-2 . 392
All . . . 2.2 3.7 3.8 7-6 . 4724
Intestine
Early . . 36.7 35.-7 38.-7 47 0 . 993
Late . . 25- 2 21.9 26*5 25 7 . 442
All . . . 14-8 13-7 15-2 15-6 . 3893
Rectum
Early . . 33- 6 38- 6 42-1 43- 8 . 1197
Late . . 19.0 17.7 25-6 24-3 . 524
All . . . 10.5 15-3 16-6 16-8 . 4324
Lung and Bronchus
Early . . 12.5 16-2 8.- 1 10-4 . 411
Late . . - 2-0 3- 8 4-0 . 622
All . . . 0.7 1*8 2-1 2 -2 . 5760
Cervix uteri
Early . . 46- 8 46- 6 44.3 46- 9 . 2720
Late . . 285 27.2 29-4 29-2 . 1979
All . . . 35.5 33.5 30-1 31-0 . 6024
Prostate
Early . . 41- 5 26- 6 23 - 7 304 . 450
Late . . 12.5 16- 5 13- 7 15- 6 . 450
All . . . 221 16.1 10.9 19- 6 . 1481
Skin
Early . . 78.5 67-9 605 61-1 . 3210
Late . . 58-8* 42 - 7* 28.6* 41.4 . 527
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Among those cases where local extension has occurred but who are still
suitable for a radical form of treatment there is rarely a regular change in survival
rates with increasing length of history but with the exception of epithe]ioma of
the skin and carcinoma of the prostate the crude survival rate of those with a
history of more than six months exceeds the rate for those with shorter duration.
The crude survival rates of all cases whether treated or not are shown in the
third line of each section of Table II. Only in cancer of the prostate and cancer of
the cervix are the survival rates of cases with a history of less than six months
higher than the rate for those with a longer history.
DISCUSSION
At no site do patients who present themselves with evidence of metastatic
spread give a symptomatic history strikingly longer than those who were registered
before metastases had appeared. In the case of cancers of the stomach and lung
and bronchus, in both sexes, the median durations are considerably shorter among
those with overt metastases than amongst those without. In cancer ofthe rectum
the differences are smaller; only among cancers ofthe cervix uteri does the median
duration of those with metastatic spread exceed that of patients first seen in
an early stage.
The history of the disease is dated from the appearance of a symptom-indiges-
tion, abdominal pain, haemorrhage, retention ofurine, or cough-which is thought
to be an indication that the growth has already grown sufficiently tointerfere with
the normal function of the body. It is of course no indication of how long the
cancerous process has preceded the symptom nor how large the growth has become
before the symptom was caused, but it is the only measure of duration available.
To consider first the group ofgastric cancers: the median duration is consider-
ably less among the metastatic group than among those in the early stage while
the symptomatic duration of those first seen in a late stage is intermediate. Not
only is the average symptomatic duration ofthe disease shorter as the severity of
the condition on registration increases but in each stage the survival rate is highest
when the history is longest. If the symptomatic history is long and the growth
still in an early stage, the intrinsic malignancy of that particular growth must be
low compared with that in a patient with a shorter symptomatic history who
already shows signs of metastastic spread. Thus it seems certain that ifthedegree
of malignancy as estimated by the rate of growth and the tendency to invasion
andmetastaticspread could be computedineach case, alargerproportion of cancers
of low malignancy would be found among those who present themselves in an
early stage ofthe disease even when the symptomatic history is long, than among
those not seen until the disease has progressed further. The coincidence ofa longer
history with a better survival rate, seen also in the early cases of cancer of the
intestine and rectum, suggests some process of weeding out has occurred, leaving
in the early stage only those growths of low intrinsic malignancy which have a
better prospect of long survival.
A similar correlation between a short symptomatic history and an advanced
stage ofgrowth is seen also in the lung and bronchus series. In cancer ofthe large
intestine, rectum and prostate no significant correlation either way can be
discerned, while the average duration of cases of cervical cancer seen in the early
stage is less than amongst those not seen until the late and metastatic stage.
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Among patients with epithelioma ofthe skin the median durationinlate cases
was in men twice and in women more than one and one half as great as in early
cases. Here we are dealing with a growth that can actually be seen, even in its
very early stages, is in general of low intrinsic malignancy, has little tendency to
produce lymphatic or distant metastases and invades adjoining structures with
comparative reluctance.
Among prostatic cancers although the early cases seen within two months
of the onset of symptoms have a much better prognosis than those seen later,
the difference in survival between early or late cases, whether the history is under
or over six months, is negligible. In the large series of cancer of the cervix uteri
the survival rates vary very little within the early group while the late cases have
a slightly better prognosis where the history exceeds six months.
The conclusions to be drawn from a study ofthese data are mainly negative in
their implications but may be expressed in three propostitions.
I. In cancer of the internal organs positive correlation between the
length of symptomatic history and the stage of the growth is infre-
quent. Advanced growths with distant metastases, especially
among the more rapidly lethal cancers, are frequently associated
with a short duration of symptoms and a long history is equally
common when a growth is still localised.
II. Prognosis as measured by the five year survival rate is in the case
ofinternal cancer almost entirely determined by the stage the growth
has reached, and it is relatively independent of the duration of
symptoms, though a betterprognosis is often associated with a longer
history.
III. Epithelioma of the skin, where the very early stages of the growth
can be visually detected, on the contrary shows a definite correlation
between a short history and an early stage, a shorter history being
more frequently associated with a better prognosis.
The observations presented above are not new; Harnett (1953) reviewed the
literature and on a basis ofthe data collected in the ' Survey ofCancer in London '
(Harnett, 1952) between 1936 and 1939, made a similar analysis for a much
greater variety of sites with very similar results. He concluded that "the rate of
growth of the tumour is the most important factor influencing the survival rate
after radical treatment, leading to relatively long survival in spite of delay in
commencing treatment." It seems also certain that the intrinsic malignancy
of a growth is an important factor in determining the attitude of the patient to
the need for seeking medical advice and to the resulting duration of symptoms
before diagnosis. This appears true at least for growths of high malignancy
and where the growth as such, is not apparent in its early stages. A change that
occurs rapidly can be expected to arouse alarm at an earlier date than one which
proceeds more slowly, and where recognition ofthe basic cause is not obvious the
condition or extent of the growth when diagnosed may be the best indication of
its intrinsic malignancy. Lees and Lees (1950) concluded that "It is probable
that more rapidly growing and intrinsically more 'malignant' tumours are on
the average more extensive at the time of diagnosis" and Bloom (1950) writing
about the prognosis of breast carcinoma suggested that "the more virulent
tumours tend to present sooner than the ones oflower malignancy ". Thus a long
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symptomatic history in a newly diagnosed early case of cancer may be regarded as
a favourable prognostic sign, if the disease is still in an operable condition. Such
a statement does not indicate that delay is not dangerous, we still know very little
about degrees of malignancy and practically nothing at all as to how they may
vary during the course of tumour growth. There is considerable evidence to show
that an apparently indolent tumour may quite suddenly assume a rapid rate of
growth while cessation of spread is not unknown as a sequel to earlier evidence
ofhigh malignancy. Conclusions arrived at from the examination oflarge numbers
ofcases are valid only for the average case, which is purely a statistical conception,
having little counterpart in clinical practice where each case differs to a greater
or less degree from the next. The findings of this paper do not disprove the view
that early diagnosis and early treatment are of the utmost importance ifsurvival
rates are to be improved.
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